In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in ...

Hoth Therapeutics has shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another ...

Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim ...

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells.

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...